Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer (2020)
- Authors:
- USP affiliated authors: SILVA, TALES ALEXANDRE DA COSTA E - FCF ; PESSOA JUNIOR, ADALBERTO - FCF ; MONTEIRO, GISELE - FCF
- Unidade: FCF
- DOI: 10.1016/j.blre.2020.100651
- Subjects: BIOFARMACOLOGIA; LEUCEMIA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Midlothian
- Date published: 2020
- Source:
- Título do periódico: Blood Reviews
- ISSN: 0268-960X
- Volume/Número/Paginação/Ano: v. 43, p. 1-17 art. 100651, 2020
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
COSTA-SILVA, Tales Alexandre et al. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Reviews, v. 43, p. 1-17 art. 100651, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.blre.2020.100651. Acesso em: 18 set. 2024. -
APA
Costa-Silva, T. A., Costa, I. M., Biasoto, H. P., Lima, G. M., Silva, C. M., Pessoa Junior, A., & Monteiro, G. (2020). Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Reviews, 43, 1-17 art. 100651. doi:10.1016/j.blre.2020.100651 -
NLM
Costa-Silva TA, Costa IM, Biasoto HP, Lima GM, Silva CM, Pessoa Junior A, Monteiro G. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer [Internet]. Blood Reviews. 2020 ; 43 1-17 art. 100651.[citado 2024 set. 18 ] Available from: https://doi.org/10.1016/j.blre.2020.100651 -
Vancouver
Costa-Silva TA, Costa IM, Biasoto HP, Lima GM, Silva CM, Pessoa Junior A, Monteiro G. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer [Internet]. Blood Reviews. 2020 ; 43 1-17 art. 100651.[citado 2024 set. 18 ] Available from: https://doi.org/10.1016/j.blre.2020.100651 - Bioprospecting and rational engineering of new L-asparaginase to present a better biopharmaceutical for blood cancer treatment
- Chemogenomic study of gemcitabine using Saccharomyces cerevisiae as model cell—molecular insights about chemoresistance
- Mutant L-asparaginase of Dickeya chrysanthemi (Erwinia chrysanthemi) with better biochemical parameters
- Functional and structural evaluation of the antileukaemic enzyme L-asparaginase II expressed at low temperature by different Escherichia coli strains
- Saccharomyces cerevisiae L-asparaginase 1: rational modifications aiming the modulation of kinetic characteristics over different substrates
- Producing L-asparaginase of Erwinia chrysanthemi improved by synthetic evolution of proteins
- Osmolytes stabilize L-asparaginase II without changing its secondary structure
- Otimização do meio de cultura para a produção de L-asparaginase extracelular em E. Coli BL21 (DE3)
- Evaluation of bacterial expression strains for the production of recombinant L-asparaginase, an antileukemic enzyme from Escherichia coli
- Evaluation of the activity and resistance to proteolytic cleavage of recombinat L-asparaginase obtained by error-prone polymerase chain reaction
Informações sobre o DOI: 10.1016/j.blre.2020.100651 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
